Q32 Bio (QTTB) Current Deferred Revenue (2017 - 2023)

Q32 Bio has reported Current Deferred Revenue for 7 years, with the latest figure at $354000.0 in Q1 2023.

• For the quarter ending Q1 2023, Current Deferred Revenue fell 88.97% year-over-year to $354000.0; the trailing twelve-month figure through Mar 2023 stood at $354000.0 (down 88.97% YoY), and the FY2022 full-year result was $1.2 million, down 63.97% from the prior year.
• Current Deferred Revenue for Q1 2023 stood at $354000.0, down from $1.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $5.6 million in Q4 2020, with the low at $354000.0 in Q1 2023.
• Average Current Deferred Revenue over 5 years is $2.1 million, with a median of $1.3 million recorded in 2019.
• Year-over-year, Current Deferred Revenue surged 569.77% in 2021 and tumbled 88.97% in 2023.
• Tracing QTTB's Current Deferred Revenue over 5 years: stood at $1.3 million in 2019, then soared by 328.94% to $5.6 million in 2020, then slumped by 43.04% to $3.2 million in 2021, then tumbled by 63.97% to $1.2 million in 2022, then plunged by 69.38% to $354000.0 in 2023.
• The last three Current Deferred Revenue figures came in at $354000.0 (Q1 2023), $1.2 million (Q4 2022), and $2.0 million (Q3 2022), per Business Quant data.

Peer Comparison